Follow The Filings

BMRN BioMarin Pharmaceutical

BioMarin Pharmaceutical earnings company data as of 11:58 AM ET 10/23

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 26 Oct EPS 1.16 — —
Rev — — —

Insider trades

Open-market buys and sales by BMRN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BMRN insider trades
  • None no insider bought on the open market
  • $4.3M sold by 3 insiders outside a trading plan
  • None no planned (10b5-1) sales
  1. George Eric Davis EVP, Chief Legal Officer
    Sale
    $1.2M 17,557 shares at $66.28 22% of stake
    Traded Sep 2 Filed Sep 3
  2. Gregory R Friberg EVP, Chief R&D Officer
    Sale
    $177K 3,281 shares at $53.85 6% of stake
    Traded May 7 Filed May 11
  3. Charles Greg Guyer EVP, Chief Technical Officer
    Sale
    $997K 16,486 shares at $60.46 17% of stake
    Traded Mar 11 Filed Mar 12
  4. Gregory R Friberg EVP, Chief R&D Officer
    Sale
    $382K 6,326 shares at $60.38 14% of stake
    Traded Feb 26 Filed Feb 26
  5. George Eric Davis EVP, Chief Legal Officer
    Sale
    $1.6M 26,061 shares at $61.36 27% of stake
    Traded Feb 26 Filed Feb 26

Also filed in the last 12 months, not counted as buying or selling: 27 stock grants and 13 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 19 shown.

Filed Form Detail Links
8-K 2.02
8-K 1.01
8-K 8.01
8-K 5.02
8-K 8.01
8-K 1.01,7.01,9.01
8-K 1.01,7.01,9.01
8-K 2.02,9.01
10-Q
8-K/A 8.01,9.01
8-K 5.02,5.07
10-Q
8-K 2.02,9.01
SCHEDULE 13G —
8-K 1.01,2.01,2.03,7.01,9.01
8-K 8.01
DEF 14A
DEFA14A
SCHEDULE 13G/A —

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.